메뉴 건너뛰기
Molecular and Cellular Oncology
Volumn 3, Issue 2, 2016, Pages
Breaking a paradigm: IL-6/STAT3 signaling suppresses metastatic prostate cancer upon ARF expression
Author keywords

ARF; CDK4 CDK6 inhibitors; IL 6; Metastasis; Prostate cancer; Senescence; STAT3
Indexed keywords

EID: 84988592197     PISSN: None     EISSN: 23723556     Source Type: Journal    
DOI: 10.1080/23723556.2015.1090048     Document Type: Article
Times cited : (9)
References (10)
  • 1
    • 34247149015 scopus 로고    scopus 로고
    • The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention
    • 17407548,; PMID
    • Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 2007 6:24; PMID:17407548; http://dx.doi.org/10.1186/1476-4598-6-24
    • (2007) Mol Cancer , vol.6 , pp. 24
    • Alao, J.P.1
  • 2
    • 84959852003 scopus 로고    scopus 로고
    • The history and future of targeting cyclin-dependent kinases in cancer therapy
    • 25633797,; PMID
    • Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 2015 14:130-46; PMID:25633797; http://dx.doi.org/10.1038/nrd4504
    • (2015) Nat Rev Drug Discov , vol.14 , pp. 130-146
    • Asghar, U.1    Witkiewicz, A.K.2    Turner, N.C.3    Knudsen, E.S.4
  • 3
    • 0034084926 scopus 로고    scopus 로고
    • Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone
    • 10815912,; PMID
    • Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 2000 6:1891-5; PMID:10815912
    • (2000) Clin Cancer Res , vol.6 , pp. 1891-1895
    • Drobnjak, M.1    Osman, I.2    Scher, H.I.3    Fazzari, M.4    Cordon-Cardo, C.5
  • 4
    • 0035180451 scopus 로고    scopus 로고
    • Interleukin-6 is an autocrine growth factor in human prostate cancer
    • 11733366,; PMID
    • Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001 159:2159-65; PMID:11733366; http://dx.doi.org/10.1016/S0002-9440(10)63067-2
    • (2001) Am J Pathol , vol.159 , pp. 2159-2165
    • Giri, D.1    Ozen, M.2    Ittmann, M.3
  • 5
    • 84942897448 scopus 로고    scopus 로고
    • TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients
    • 25967142,; PMID
    • Hossain DM, Pal SK, Moreira D, Duttagupta P, Zhang Q, Won H, Jones J, D'Apuzzo M, Forman S, Kortylewski M. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients. Clin Cancer Res 2015 21:3771-82; PMID:25967142; http://dx.doi.org/10.1158/1078-0432.CCR-14-3145
    • (2015) Clin Cancer Res , vol.21 , pp. 3771-3782
    • Hossain, D.M.1    Pal, S.K.2    Moreira, D.3    Duttagupta, P.4    Zhang, Q.5    Won, H.6    Jones, J.7    D'Apuzzo, M.8    Forman, S.9    Kortylewski, M.10
  • 6
    • 79956160855 scopus 로고    scopus 로고
    • The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study
    • 21321981,; PMID
    • Karkera J, Steiner H, Li W, Skradski V, Moser PL, Riethdorf S, Reddy M, Puchalski T, Safer K, Prabhakar U, et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate 2011 71:1455-65; PMID:21321981; http://dx.doi.org/10.1002/pros.21362
    • (2011) Prostate , vol.71 , pp. 1455-1465
    • Karkera, J.1    Steiner, H.2    Li, W.3    Skradski, V.4    Moser, P.L.5    Riethdorf, S.6    Reddy, M.7    Puchalski, T.8    Safer, K.9    Prabhakar, U.10
  • 7
    • 1842668004 scopus 로고    scopus 로고
    • Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells
    • 12538490,; PMID
    • Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003 9:370-6; PMID:12538490
    • (2003) Clin Cancer Res , vol.9 , pp. 370-376
    • Lee, S.O.1    Lou, W.2    Hou, M.3    de Miguel, F.4    Gerber, L.5    Gao, A.C.6
  • 9
    • 79957888198 scopus 로고    scopus 로고
    • Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies
    • 21625400,; PMID
    • Tawara K, Oxford JT, Jorcyk CL. Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res 2011 3:177-89; PMID:21625400
    • (2011) Cancer Manag Res , vol.3 , pp. 177-189
    • Tawara, K.1    Oxford, J.T.2    Jorcyk, C.L.3
  • 10
    • 33645514605 scopus 로고    scopus 로고
    • Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice
    • 16540658,; PMID
    • Wallner L, Dai J, Escara-Wilke J, Zhang J, Yao Z, Lu Y, Trikha M, Nemeth JA, Zaki MH, Keller ET. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res 2006 66:3087-95; PMID:16540658; http://dx.doi.org/10.1158/0008-5472.CAN-05-3447
    • (2006) Cancer Res , vol.66 , pp. 3087-3095
    • Wallner, L.1    Dai, J.2    Escara-Wilke, J.3    Zhang, J.4    Yao, Z.5    Lu, Y.6    Trikha, M.7    Nemeth, J.A.8    Zaki, M.H.9    Keller, E.T.10

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.